Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Comparison of 11 automated PET segmentation methods in lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Marie José Kersten
  • Julia Driessen
  • Josée M Zijlstra
  • Wouter J Plattel
  • Franck Morschhauser
  • Pieternella J Lugtenburg
  • Pauline Brice
  • Martin Hutchings
  • Thomas Gastinne
  • Roberto Liu
  • Coreline N Burggraaff
  • Marcel Nijland
  • Sanne H Tonino
  • Anne IJ Arens
  • Roelf Valkema
  • Harm van Tinteren
  • Marta Lopez-Yurda
  • Arjan Diepstra
  • Daphne De Jong
  • Anton Hagenbeek
Vis graf over relationer

Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: NCT02280993.

OriginalsprogEngelsk
TidsskriftHaematologica
Vol/bind106
Udgave nummer4
Sider (fra-til)1129-1137
Antal sider9
ISSN0390-6078
DOI
StatusUdgivet - 1 apr. 2021

Bibliografisk note

Copyright © 2020, Ferrata Storti Foundation.

ID: 62112358